Business Context and Reporting Period
This Form 8-K was filed by BioZone Pharmaceuticals, Inc. (not Cocrystal Pharma, Inc.) on September 20, 2012. The report details a material definitive agreement involving the termination of a prior license and the cessation of specific research and development activities.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on contractual changes rather than financial performance metrics.
Material Changes
- Termination of License: The Company terminated a February 12, 2012 License Agreement with consultant Nian Wu regarding "Sugar Lipid Technology" for Propofol formulation.
- Stock Cancellation: Mr. Wu tendered 6,650,000 shares of common stock for cancellation, which were originally issued in June 2011 for patent rights.
- Operational Cessation: The Company terminated all R&D activities and associated personnel in Princeton, New Jersey.
- Lease Assumption: Mr. Wu agreed to use best efforts to assume the Company's lease for the Princeton facility.
- New Licensing Arrangement: A new Limited License Agreement was executed granting Mr. Wu a non-exclusive worldwide license to certain patents. Both parties agreed to pay each other a 5% royalty on net sales of Covered Products and share 50% of fees from sublicensing rights.
Outlook, Risks, and Contingencies
The filing indicates a strategic pivot away from the specific Propofol formulation efforts in Princeton. The new agreement creates a contingent royalty obligation for the Company based on future net sales of products relying on the licensed patents. The agreement remains effective until the expiration of the last licensed patent unless terminated earlier.
Investor Verification Checklist
- Verify the impact of the 6,650,000 share cancellation on the Company's outstanding share count and capitalization.
- Confirm the financial implications of terminating the Princeton R&D facility and personnel.
- Review the specific patents covered under the new Limited License Agreement to assess future royalty exposure.
- Clarify the status of the distribution rights previously granted to Opko Health, Inc., which were terminated as part of this agreement.